Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23612572 | 0.78 | MEN1 (0.35) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12415477 | 0.78 | ALDH1A1 (0.32) | KMT2AALDH1A1 | |
| SCHEMBL12415486 | 0.77 | PIK3CD (0.35) | MEN1KMT2ASMN1; SMN2ALDH1A1FAAH | |
| SCHEMBL12415492 | 0.74 | ALDH1A1 (0.34) | MEN1KMT2ASMN1; SMN2ALDH1A1FAAH | |
| SCHEMBL12534614 | 0.73 | MEN1 (0.35) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12415479 | 0.73 | ALDH1A1 (0.36) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL19130398 | 0.73 | HSD17B10 (0.36) | ALDH1A1 | |
| SCHEMBL12534609 | 0.71 | MEN1 (0.37) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12415487 | 0.70 | ALDH1A1 (0.37) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL12308316 | 0.69 | ALDH1A1 (0.59) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080984-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | RCSD1, RRP12, TIAM1 | MEN1 1844/4885KMT2A 3970/4885SMN1; SMN2 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.